U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin - Hallo friendsLET'S HEALTHY LIFE, In the article you read this time with the title U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article cough, Article diabetes, Article diseases, Article in general, Article Phytotherapy, Article skin diseases, We write this you can understand. Alright, good read.

Title : U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin
link : U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin

U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin

A panel of federal health advisers has narrowly recommended approval for an experimental antibiotic from Cempra Inc., a small North Carolina drugmaker.

The Food and Drug Administration's outside experts voted 7-6 in favor of the drug, saying its effectiveness outweighed risks of liver toxicityseen in company studies. The vote is nonbinding but the FDA often follows the advice of its panelists.

Cempra is one of a handful of drugmakers developing new antibiotics amid growing bacterial resistance to decades-old drugs like penicillin.

On Wednesday Cempra shares plunged more than 60 percent after the FDA posted an online review highlighting irregular liver enzyme measurements reported with the drug, called solithromycin. 

U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin

Medicinal Chemistry

Thus Article U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin

That's an article U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin with the link address https://letslifes.blogspot.com/2017/08/us-fda-panel-narrowly-backs-cempras.html

Tweet

Subscribe to receive free email updates: